548 related articles for article (PubMed ID: 36412155)
1. [Evolution of the diagnostic frontiers of Alzheimer's disease and new therapeutic possibilities].
Gavrilova SI
Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(11. Vyp. 2):38-44. PubMed ID: 36412155
[TBL] [Abstract][Full Text] [Related]
2. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
[TBL] [Abstract][Full Text] [Related]
3. [Early detection of Alzheimer's disease and dementia prediction in patients with mild cognitive impairment : Summary of current recommendations].
Rostamzadeh A; Jessen F
Nervenarzt; 2020 Sep; 91(9):832-842. PubMed ID: 32300816
[TBL] [Abstract][Full Text] [Related]
4. [The new 2011 recommendations of the National Institute on Aging and the Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinal stages, mild cognitive impairment, and dementia].
Croisile B; Auriacombe S; Etcharry-Bouyx F; Vercelletto M; ;
Rev Neurol (Paris); 2012 Jun; 168(6-7):471-82. PubMed ID: 22579080
[TBL] [Abstract][Full Text] [Related]
5. A data-driven model of biomarker changes in sporadic Alzheimer's disease.
Young AL; Oxtoby NP; Daga P; Cash DM; Fox NC; Ourselin S; Schott JM; Alexander DC;
Brain; 2014 Sep; 137(Pt 9):2564-77. PubMed ID: 25012224
[TBL] [Abstract][Full Text] [Related]
6. Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes.
Carandini T; Arighi A; Sacchi L; Fumagalli GG; Pietroboni AM; Ghezzi L; Colombi A; Scarioni M; Fenoglio C; De Riz MA; Marotta G; Scarpini E; Galimberti D
Alzheimers Res Ther; 2019 Oct; 11(1):84. PubMed ID: 31615545
[TBL] [Abstract][Full Text] [Related]
7. Development of molecular tools for diagnosis of Alzheimer's disease that are based on detection of amyloidogenic proteins.
Kulichikhin KY; Fedotov SA; Rubel MS; Zalutskaya NM; Zobnina AE; Malikova OA; Neznanov NG; Chernoff YO; Rubel AA
Prion; 2021 Dec; 15(1):56-69. PubMed ID: 33910450
[TBL] [Abstract][Full Text] [Related]
8. Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
Ritchie C; Smailagic N; Noel-Storr AH; Takwoingi Y; Flicker L; Mason SE; McShane R
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD008782. PubMed ID: 24913723
[TBL] [Abstract][Full Text] [Related]
9. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
Apostolova LG; Hwang KS; Kohannim O; Avila D; Elashoff D; Jack CR; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
Neuroimage Clin; 2014; 4():461-72. PubMed ID: 24634832
[TBL] [Abstract][Full Text] [Related]
10. β-Amyloid in blood neuronal-derived extracellular vesicles is elevated in cognitively normal adults at risk of Alzheimer's disease and predicts cerebral amyloidosis.
Li TR; Yao YX; Jiang XY; Dong QY; Yu XF; Wang T; Cai YN; Han Y
Alzheimers Res Ther; 2022 May; 14(1):66. PubMed ID: 35550625
[TBL] [Abstract][Full Text] [Related]
11. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.
Gangishetti U; Christina Howell J; Perrin RJ; Louneva N; Watts KD; Kollhoff A; Grossman M; Wolk DA; Shaw LM; Morris JC; Trojanowski JQ; Fagan AM; Arnold SE; Hu WT
Alzheimers Res Ther; 2018 Sep; 10(1):98. PubMed ID: 30253800
[TBL] [Abstract][Full Text] [Related]
12. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.
Jack CR; Bennett DA; Blennow K; Carrillo MC; Dunn B; Haeberlein SB; Holtzman DM; Jagust W; Jessen F; Karlawish J; Liu E; Molinuevo JL; Montine T; Phelps C; Rankin KP; Rowe CC; Scheltens P; Siemers E; Snyder HM; Sperling R;
Alzheimers Dement; 2018 Apr; 14(4):535-562. PubMed ID: 29653606
[TBL] [Abstract][Full Text] [Related]
13. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
14. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
[TBL] [Abstract][Full Text] [Related]
15. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
[TBL] [Abstract][Full Text] [Related]
16. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
[TBL] [Abstract][Full Text] [Related]
17. Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer's dementia in mild cognitive impairment patients.
Pichet Binette A; Palmqvist S; Bali D; Farrar G; Buckley CJ; Wolk DA; Zetterberg H; Blennow K; Janelidze S; Hansson O
Alzheimers Res Ther; 2022 Mar; 14(1):46. PubMed ID: 35351181
[TBL] [Abstract][Full Text] [Related]
18. Biomarkers with Plasma Amyloid β and Tau Protein Assayed by Immunomagnetic Reduction in Patients with Amnestic Mild Cognitive Impairment and Alzheimer's Disease.
Lee PJ; Tsai CL; Liang CS; Peng GS; Lee JT; Tsai CK; Lin YK; Yang FC
Acta Neurol Taiwan; 2022 Jun; 31(2)():53-60. PubMed ID: 35040113
[TBL] [Abstract][Full Text] [Related]
19. Matrix metalloproteinase 10 is linked to the risk of progression to dementia of the Alzheimer's type.
Martino Adami PV; Orellana A; García P; Kleineidam L; Alarcón-Martín E; Montrreal L; Aguilera N; Espinosa A; Abdelnour C; Rosende-Roca M; Pablo Tartari J; Vargas L; Mauleón A; Esteban-De Antonio E; López-Cuevas R; Dalmasso MC; Campos Martin R; Parveen K; Andrade Fuentes VM; Amin N; Ahmad S; Ikram MA; Lewczuk P; Kornhuber J; Peters O; Frölich L; Rüther E; Wiltfang J; Tarraga L; Boada M; Maier W; de Rojas I; Cano A; Sanabria A; Alegret M; Hernández I; Marquié M; Valero S; van Duijn CM; Wagner M; Jessen F; Schneider A; Sáez Goñi ME; González Pérez A; Ruiz A; Ramírez A
Brain; 2022 Jul; 145(7):2507-2517. PubMed ID: 35088840
[TBL] [Abstract][Full Text] [Related]
20. Plasma Aβ42/40 Ratio Detects Early Stages of Alzheimer's Disease and Correlates with CSF and Neuroimaging Biomarkers in the AB255 Study.
Pérez-Grijalba V; Romero J; Pesini P; Sarasa L; Monleón I; San-José I; Arbizu J; Martínez-Lage P; Munuera J; Ruiz A; Tárraga L; Boada M; Sarasa M
J Prev Alzheimers Dis; 2019; 6(1):34-41. PubMed ID: 30569084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
